MetaCap

Arcutis Biotherapeutics (ARQT) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 148.5% versus a loss of 10.6%. Over five years, XERS leads with a +682.0% price change compared with +58.1% for ARQT. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.10 billion), about 1.1 times the size.

On valuation, Arcutis Biotherapeutics trades at a lower forward P/E (24.1x vs 63.6x for Xeris Biopharma). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -4.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARQT-10.61%XERS+148.46%
+158%+57%-43%
Nov 21, 20251 yearNov 20, 2026
ARQT+44.91%XERS+647.58%
+684%+279%-126%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARQT versus XERS key metrics
MetricARQTXERS
Share price$26.36$16.97
Market cap$3.33B$3.10B
1-day change-2.98%+2.11%
YTD return-9.23%+116.18%
1-year return-10.61%+148.46%
5-year return+58.13%+682.03%
P/E ratio (TTM)119.82—
Forward P/E24.0963.64
EPS (TTM)$0.22$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$376.07M$291.85M
Revenue growth (YoY)+91.34%+43.72%
Net income (latest FY)$-16.14M$554.00K
Gross margin90.24%85.41%
Operating margin-3.25%8.53%
Net margin-4.29%0.19%
52-week high$34.80$17.28
52-week low$19.30$5.25
Distance from 52-week high-24.25%-1.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.19%+1.89%
Average volume2.58M2.86M
Shares outstanding126.46M182.70M
Employees354435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed ARQT by 159.1 percentage points over the past year.
  • Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs +43.72%).

About Arcutis Biotherapeutics

ARQT stock →

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

ARQT vs XERS FAQ

Which is bigger, Arcutis Biotherapeutics or Xeris Biopharma?

Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.10B for Xeris Biopharma (XERS).

Which stock has performed better over the past year, ARQT or XERS?

XERS returned +148.46% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.

Are Arcutis Biotherapeutics and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons